COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND

被引：0
|
作者：
Sruamsiri, R. [1 ]
机构：
[1] Takeda Thailand Ltd, Bangkok, Thailand
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.015
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE3
引用
收藏
页码：S2 / S2
页数：1
相关论文
共 50 条
  • [31] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [32] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [33] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [34] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [35] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Kobayashi, Taku
    Hoshi, Masato
    Yuasa, Akira
    Arai, Shoko
    Ikeda, Mitsunobu
    Matsuda, Hiroyuki
    Kim, Seok-Won
    Hibi, Toshifumi
    PHARMACOECONOMICS, 2023, 41 (05) : 589 - 604
  • [36] Etrolizumab in moderate-to-severe ulcerative colitis
    Armuzzi, Alessandro
    Felice, Carla
    LANCET, 2014, 384 (9940): : 285 - 286
  • [37] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE
    Vellopoulou, K.
    Stefanou, G.
    Tzanetakos, C.
    Boubouchairopoulou, N.
    Nakou, M.
    Kourlaba, G.
    VALUE IN HEALTH, 2019, 22 : S619 - S620
  • [38] Cost-Effectiveness of Golimumab Versus Infliximab and Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis
    Druyts, Kristian Thorlund Eric
    Kanters, Steve
    Eapen, Shawn
    Mills, Edward
    GASTROENTEROLOGY, 2014, 146 (05) : S202 - S202
  • [39] COST-EFFECTIVENESS OF GOLIMUMAB VERSUS INFLIXIMAB AND ADALIMUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS
    Thorlund, K.
    Druyts, E.
    Eapen, S.
    Mills, E.
    VALUE IN HEALTH, 2014, 17 (03) : A38 - A38
  • [40] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
12345